 Cost-Benefit Analysis
"Cost-Benefit Analysis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. Cost effectiveness compares alternative ways to achieve a specific set of results.
| Descriptor ID |
D003362
|
| MeSH Number(s) |
N03.219.151.125
|
| Concept/Terms |
Cost-Benefit Analysis- Cost-Benefit Analysis
- Analyses, Cost-Benefit
- Analysis, Cost-Benefit
- Cost-Benefit Analyses
- Cost Benefit Analysis
- Analyses, Cost Benefit
- Analysis, Cost Benefit
- Cost Benefit Analyses
Cost-Utility Analysis- Cost-Utility Analysis
- Analyses, Cost-Utility
- Analysis, Cost-Utility
- Cost Utility Analysis
- Cost-Utility Analyses
Economic Evaluation- Economic Evaluation
- Economic Evaluations
- Evaluation, Economic
- Evaluations, Economic
Marginal Analysis- Marginal Analysis
- Analyses, Marginal
- Analysis, Marginal
- Marginal Analyses
Cost Benefit- Cost Benefit
- Costs and Benefits
- Benefits and Costs
|
Below are MeSH descriptors whose meaning is more general than "Cost-Benefit Analysis".
Below are MeSH descriptors whose meaning is more specific than "Cost-Benefit Analysis".
This graph shows the total number of publications written about "Cost-Benefit Analysis" by people in this website by year, and whether "Cost-Benefit Analysis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 | | 1996 | 0 | 2 | 2 | | 1997 | 0 | 5 | 5 | | 1998 | 0 | 6 | 6 | | 1999 | 0 | 2 | 2 | | 2000 | 1 | 7 | 8 | | 2001 | 0 | 6 | 6 | | 2002 | 0 | 6 | 6 | | 2003 | 0 | 4 | 4 | | 2004 | 0 | 6 | 6 | | 2005 | 2 | 14 | 16 | | 2006 | 0 | 12 | 12 | | 2007 | 0 | 12 | 12 | | 2008 | 0 | 5 | 5 | | 2009 | 0 | 18 | 18 | | 2010 | 0 | 11 | 11 | | 2011 | 0 | 14 | 14 | | 2012 | 1 | 24 | 25 | | 2013 | 1 | 13 | 14 | | 2014 | 2 | 26 | 28 | | 2015 | 3 | 29 | 32 | | 2016 | 6 | 23 | 29 | | 2017 | 8 | 13 | 21 | | 2018 | 6 | 23 | 29 | | 2019 | 5 | 23 | 28 | | 2020 | 6 | 26 | 32 | | 2021 | 2 | 26 | 28 | | 2022 | 1 | 15 | 16 | | 2023 | 0 | 10 | 10 | | 2024 | 8 | 13 | 21 | | 2025 | 0 | 12 | 12 |
To return to the timeline, click here.
Below are the most recent publications written about "Cost-Benefit Analysis" by people in Profiles.
-
Stanley KJ, Chisholm C, Gillespie MK, Caluseriu O, Del Signore N, Elango S, Hartley T, Hewson S, Kim RH, McSheffrey G, Mendoza-Londono R, Sawyer SL, Somerville M, Venkataramanan V, White-Brown A, Telesca S, Shickh S, Marshall CR, Ungar WJ, Hayeems RZ, Bhawra J, Boycott KM, Costain G. TRIAGE-GS: protocol for a randomised controlled trial of a genomics-first approach to rare disease diagnosis for patients awaiting assessment by a clinical geneticist. BMJ Open. 2025 Aug 10; 15(8):e107603.
-
Kline DM, Padmanabhan P, Brewer SE, Cerdá M, Versen E, Keyes KM, Kushel M, Wilson EC, Wesson P, Hyder A, Boyer A, Al-Tayyib A, Barocas JA. Improving health and housing outcomes through a simulation and economic model: an evidence-based protocol of a group model building approach to develop an agent-based model. Front Public Health. 2025; 13:1623385.
-
Rewers M. Health economic considerations of screening for early type 1 diabetes. Diabetes Obes Metab. 2025 08; 27 Suppl 6:69-77.
-
Zemplenyi AT, Chen NC, Anderson KE, Adamson B, DiStefano MJ, Nair KV, McQueen RB. Key Considerations for Assessing Real-World Comparative Effectiveness in the Context of the Drug Price Negotiation Program: A Case Study of Pembrolizumab. Pharmacoeconomics. 2025 Sep; 43(9):1147-1160.
-
Carlson AL, Badlani S, Shah VN. The Role, Potential Benefits and Cost-effectiveness of Digital Tools for Diabetes Management. Clin Ther. 2025 Aug; 47(8):638-648.
-
Peace A, White DA, Hackney G, Bradburn M, Norman P, White S, Al-Chalabi A, Baird W, Beever D, Cade J, Coates E, Cooper C, Ezaydi N, Halliday V, Maguire C, Shaw PJ, Stavroulakis H, Waterhouse S, Young TA, McDermott CJ. Randomised controlled trial with parallel process evaluation and health economic analysis to evaluate a nutritional management intervention, OptiCALS, for patients with amyotrophic lateral sclerosis: study protocol. BMJ Open. 2025 May 27; 15(5):e096098.
-
Doan TT, Hutton DW, Wright DR, Prosser LA. Cost-Effectiveness of Universal Routine Depression Screening for Adolescents in Primary Care. JAMA Health Forum. 2025 May 02; 6(5):e250711.
-
Sanders J, Greenhawt M, Oppenheimer J, Anagnostou A, Shaker MS. Value-based care in allergy-immunology: Beyond the quality-adjusted life year. Allergy Asthma Proc. 2025 May 01; 46(3):165-167.
-
Patterson JK, Neuwahl S, Kirsch S, Moore JL, Tita ATN, Carlo WA, Lokangaka A, Tshefu A, Mwenechanya M, Chomba E, Kavi A, Metgud MC, Goudar SS, Derman RJ, Shivkumar P, Waikar M, Patel A, Hibberd PL, Nyongesa P, Esamai F, Ekhaguere OA, Bucher S, Jessani S, Tikmani SS, Saleem S, Wylie BJ, Goldenberg RL, Billah SM, Lennox R, Haque R, Petri WA, Mazariegos M, Krebs NF, Hemingway-Foday JJ, Babineau D, Koso-Thomas M, McClure EM, Bauserman M. Cost-effectiveness of intrapartum azithromycin to prevent maternal infection, sepsis, or death in low-income and middle-income countries: a modelling analysis of data from a randomised, multicentre, placebo-controlled trial. Lancet Glob Health. 2025 04; 13(4):e679-e688.
-
Gidwani R, Saylor KW, Russell LB. Health State Utility Values: The Implications of Patient versus Community Ratings in Assessing the Value of Care. Med Decis Making. 2025 May; 45(4):347-357.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|